Impact of a Cystic Fibrosis Specific Multivitamin Formulation on Fat-Soluble Vitamin Status and Treatment
Anne Munck1, Raphael Enaud2, Jeanne Languepin3
1Hospital Necker Enfants Malades, CF Center, 75015 Paris, France.
Insights
Switching to DEKAs Plus Liquid (DPL) improved fat-soluble vitamin levels and treatment satisfaction in children with cystic fibrosis (CF). This CF-specific multivitamin formulation reduced vitamin deficiencies and enhanced patient well-being.
Area of Science:
- Pediatric Gastroenterology
- Nutritional Science
- Cystic Fibrosis Research
Background:
- Children with cystic fibrosis (CF) often experience fat malabsorption, increasing their risk of fat-soluble vitamin (FSV) deficiencies.
- Previously, French CF patients used individual vitamin preparations; a transition to DEKAs Plus Liquid (DPL), a specialized multivitamin, was implemented.
- DPL is designed for enhanced absorption and includes vitamins D3, E, K1, A, B, C, zinc, and selenium.
Purpose of the Study:
- To evaluate the impact of switching from individual vitamin supplements to DEKAs Plus Liquid (DPL) in young children with CF.
- To assess changes in fat-soluble vitamin (FSV) levels, treatment satisfaction, and compliance after the supplement switch.
Main Methods:
- Retrospective analysis of 39 young children with CF (mean age 2.3 ± 1.1 years).
- Serum FSV levels and prothrombin time were measured at baseline (M0) and 12 months (M12).
- Treatment satisfaction and compliance were assessed using validated scales at M0 and M12.
Main Results:
- Significant increases in median serum levels of vitamin E (p=0.0002) and vitamin D (p=0.04) were observed.
- The overall number of FSV deficiencies decreased from 10 to 1, with vitamin D deficiency eliminated.
- Treatment satisfaction scores significantly improved (p=0.0006), while compliance remained high (p=0.4).
Conclusions:
- The transition to DEKAs Plus Liquid (DPL) effectively reduced vitamin deficiencies in children with CF.
- The DPL formulation led to improved fat-soluble vitamin levels and significantly enhanced patient treatment satisfaction.
- DPL represents a beneficial CF-specific multivitamin strategy for improving nutritional status and adherence.
Background:
Children with cystic fibrosis (CwCF) are at increased risk of fat-soluble vitamin (FSV) deficiency due to fat malabsorption. In France, children were usually supplemented with multiple individual vitamin preparations but have recently converted to DEKAs Plus Liquid (DPL), an absorption-enhanced, CF-specific, multivitamin formulation that includes vitamins D3, E, K1, A (beta-carotene and retinol), B, C, zinc, and selenium. We evaluated the impact of this change on FSV levels, treatment satisfaction, and compliance.
Methods:
Young CwCF (n = 39, mean age 2.3 ± 1.1 years) were analyzed retrospectively. Serum FSV levels, prothrombin time, treatment satisfaction, and compliance were assessed at baseline (M0) and after 12 months (M12).
Results:
Paired data analysis was performed on the 34 who completed 12 months. After 3 months, the initial daily dose was adjusted in nine cases. Median (interquartile range) serum levels of vitamin E (19.3 (17-27) vs. 26.3 (20-31) µmol/L, p = 0.0002) and 25-hydroxyvitamin D (80.2 (68-91) vs. 88.5 (79-108) nmol/L, p = 0.04) increased. Prothrombin time and vitamin A levels showed no significant change (p = 0.7, p = 0.4, respectively). The total number of FSV deficiencies decreased from 10 to 1, vitamin D deficiency was eliminated, and vitamin K1 supplementation increased from 76% to 100% (p = 0.008). The median treatment satisfaction score (VAS1-10) improved from 7 (5-9) to 9 (9-10) (p = 0.0006). Patient compliance remained high (9.5 (8.5-10) vs. 10 (9-10), p = 0.4).
Conclusions:
Switching from individual vitamins to DPL reduced vitamin deficiencies and improved FSV levels and patient satisfaction.
More Related Videos
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
Related Concept Videos
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:30Vitamins
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...